APOBEC3G/3A Expression in Human Immunodeficiency Virus Type 1-Infected Individuals Following Initiation of Antiretroviral Therapy Containing Cenicriviroc or Efavirenz

Melanoma and Skin CancerImmunodeficiency

Association of Multiple Primary Skin Cancers With Human Immunodeficiency Virus Infection, CD4 Count, and Viral Load

JAMA Dermatol.

Asgari MM, Ray GT, Quesenberry CP Jr, Katz KA, Silverberg MJ

doi: 10.1001/

T Cells

Reduced PD-1 expression on circulating follicular and conventional FOXP3⁺ Treg cells in children with new onset type 1 diabetes and autoantibody-positive at-risk children

Clin Immunol.

Vecchione A, Gerosa J, Di Fonte R, Jofra T, Pia CM, Napoleone V, Ippolito E, Galvani G, Ragogna F, Stabilini A, Bianconi E, Grogan P, Bonura C, Bonfanti R, Frontino G, Nano R, Melzi R, De Pellegrin M, Laurenzi A, Meschi F, Barera G, Rigamonti A, Indirli R, Bosi E, Piemonti L, Aiuti A, Battaglia M, Fousteri G

doi: 10.1016/j.clim.2019.108319.

Further Publications Dermatology

Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study

Lancet HIV

Ruel TD, Capparelli EV, Tierney C, Nelson BS, Coletti A, Bryson Y, Cotton MF, Spector SA, Mirochnick M, LeBlanc R, Reding C, Zimmer B, Persaud D, Bwakura-Dangarembizi M, Naidoo KL, Hazra R, Jean-Philippe P, Chadwick EG

doi: 10.1016/S2352-3018(20)30274-5

Rheumatoid Arthritis

Rheumatic manifestations associated with Chikungunya virus infection: A study of 307 patients with 32-month follow-up (RHUMATOCHIK study)

Joint Bone Spine.

Bouquillard E, Fianu A, Bangil M, Charlette N, Ribéra A, Michault A, Favier F, Simon F, Flipo RM

doi: 10.1016/j.jbspin.2017.01.014.

Melanoma and Skin Cancer

Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy

Eur J Cancer

Hepner A, Atkinson VG, Larkin J, Burrell RA, Carlino MS, Johnson DB, Zimmer L, Tsai KK, Klein O, Lo SN, Haydon A, Bhave P, Lyle M, Pallan L, Pires da Silva I, Gerard C, Michielin O, Long GV, Menzies AM

doi: 10.1016/j.ejca.2021.04.021

COMMENTED

Immunotherapy

Retro-inverso D-peptides as a novel targeted immunotherapy for Type 1 diabetes

★ 0 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

J Autoimmun

Lombardi A, Concepcion E, Hou H, Arib H, Mezei M, Osman R, Tomer Y

doi: 10.1016/j.jaut.2020.102543

Autoimmune Disease

Autoimmune liver disease serology in acute hepatitis E virus infection

J Autoimmun.

Terziroli Beretta-Piccoli B, Ripellino P, Gobbi C, Cerny A, Baserga A, Di Bartolomeo C, Bihl F, Deleonardi G, Melidona L, Grondona AG, Mieli-Vergani G, Vergani D, Muratori L; Swiss Autoimmune Hepatitis Cohort Study Group

doi: 10.1016/j.jaut.2018.07.006.

Rheumatoid Arthritis

Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial

Ann Rheum Dis.

Atsumi T, Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Yasuda S, Yamanishi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Togo O, Okada T, van der Heijde D, Miyasaka N, Koike T

doi: 10.1136/annrheumdis-

COMMENTED

Further Publications Dermatology

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

★ 2 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

Lancet

Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, Mao H, Cui X, Karanikas CA, Thieu VT

doi: 10.1016/S0140-6736(21)01324-6

Related content